Herbal Mixtures Containing the Mushroom <i>Ganoderma lucidum</i> Improve Recovery Time in Patients with Herpes Genitalis and Labialis

Hijikata, Yasuyo; Yamada, Seika; Yasuhara, Akihiro

doi:10.1089/acm.2006.6297

Cited by 21 publications

(19 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The samples were analysed using either mass spectrometry, gas chromatography, isotope ratio mass spectrometry or infrared laser spectrometry, based on the micro-organisms under investigation and the sensitivity of the instrumentation required. Five studies (Agrawal et al, 1997;Cai et al, 2009;Hijikata et al, 2007;Gotteland et al, 2008;Wright et al, 2009) reported statistical significance in benefit claims of the PFS on specific outcomes against the different infectious diseases. Urine dip stick test Bailey, 2007, Mcmurdo 2005 Helicobacter pylori bacteria Quick and inexpensive method Non-quantitative 13 C urea breath test Shmuely, 2007, Gotteland, 2008, Nakajima, 2006 Helicobacter pylori bacteria Non-invasive, quick method Non-quantitative…”

Section: Methods For Evaluating the Benefits Of Pfs As Anti-infectivesmentioning

confidence: 99%

“…Cranberry has been the most studied plant used in PFS for its anti-bacterial properties in treating urinary tract infections and shows activity against Helicobacter pylori, the bacteria that causes stomach ulcers. 10 Prunus armeniaca L. (Armeniaca vulgaris Lam., Apricot) Nakajima, 2006 Different study designs were used ranging from an open trial with no placebo or control and no randomization (Bailey, Dalton, Daugherty, & Tempesta, 2007;Hijikata, Yamada, & Yasuhara, 2007;Maek-a-nantawat, Phonrat, Dhitavat, Naksrisook, Muanaum, Ngamdee, & Pitisuttithum, 2009;Nakajima, Fujita, Inoue, Nishio, & Seto, 2006;Davis, Shen, & Cai, 1990;Caporaso, Smith, & Eng, 1983) to double blind randomized placebo controlled trial including crossover (Mcmurdo, Bissett, Price, Phillips, & Crombie, 2005;Gotteland et al, 2008).…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

“…The two studies (Hijikata et al, 2007, Maek-a-nantawatet al, 2009) identified for evaluating the anti-viral potential of PFS investigated herbal mixtures and not individual plants.…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

“…The PFS were administered either orally in different dosage forms (capsule or juice), or were administered intravenously. PFS formulations were either sourced from commercial manufacturers and suppliers (Hijikata et al, 2007;Maek-a-nantawat et al, 2009;Nakajima et al, 2006;Bailey et al, 2007;Shmuely et al, 2007;Mcmurdo et al, 2005;Gotteland et al, 2008), or the manufacturing source of the formulation was not stipulated (Antiparasitic: Agrawal et al, 1997, Okeniyi et al, 2007Antifungal: Wright et al, 2009;Caporaso et al, 1983;Davis et al, 1990;Antibacterial: Caiet al, 2009 ).…”

Section: Plant Food Supplementsmentioning

confidence: 99%

“…Half the studies did not report on adverse effects (Agrawal et al, 1997;Bailey et al, 2007;Shmuely et al, 2007;Gotteland et al, 2008;Okeniyiet al, 2007;Hijikata et al, 2007;Cai et al, 2009). One study conducted on cranberry PFS (Mcmurdo et al, 2005) reported deaths in both the treatment and control groups.…”

Section: Adverse Eventsmentioning

confidence: 99%

See 4 more Smart Citations

A review of the Experimental Approaches Used in Clinical Studies to Evaluate the Health Benefits of Plant Food Supplements Associated With Infectious Diseases

Naidoo¹,

Mancama²,

Meoni³

et al. 2015

JFR

View full text Add to dashboard Cite

The objective of this review was to evaluate the experimental approaches used in clinical trials to support the benefit claims of plant food supplements (PFS) with reported activity on infectious diseases. A literature search was conducted on a list of 309 plant species currently used in food supplements in Europe using the National Centre for Biotechnology Information (NCBI) PubMed Database to identify all the clinical trials for evaluating the benefit claim for preventing or treating infectious diseases in humans. The searches included a combination of terms related to the name of plants, class of infectious agents and therapeutic activities against infectious disease. By limiting the searches to clinical studies, only 27 articles representing 19 plant species were identified. From this list, 13 papers from the 10 plants most extensively researched were critically evaluated for assessing methods used to assess the benefits of PFS. Different study designs were used ranging from an open trial with no placebo or control and no randomization to double-blind randomized placebo controlled trials including a crossover design. Although the experimental approaches described in this review were found to be suitable for evaluating the benefit claims of PFS for treating infectious diseases caused by bacteria, viruses, fungi and parasites, the clinical study design should be more standardised as many studies lacked a control group and sufficient population size to be statistically acceptable taking into consideration patient variability. The reporting of the results varied and should also be standardised to include all the study parameters and data collected.

show abstract

Section: Methods For Evaluating the Benefits Of Pfs As Anti-infectivesmentioning

confidence: 99%

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

“…The two studies (Hijikata et al, 2007, Maek-a-nantawatet al, 2009) identified for evaluating the anti-viral potential of PFS investigated herbal mixtures and not individual plants.…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

Section: Plant Food Supplementsmentioning

confidence: 99%

Section: Adverse Eventsmentioning

confidence: 99%

See 3 more Smart Citations

A review of the Experimental Approaches Used in Clinical Studies to Evaluate the Health Benefits of Plant Food Supplements Associated With Infectious Diseases

Naidoo¹,

Mancama²,

Meoni³

et al. 2015

JFR

View full text Add to dashboard Cite

show abstract

Current landscape in antiviral drug development against herpes simplex virus infections

2022

View full text Add to dashboard Cite

Herpes simplex viruses (HSV) are common human pathogens with a combined global seroprevalence of 90% in the adult population. HSV‐1 causes orofacial herpes but can cause severe diseases, such as the potentially fatal herpes encephalitis and herpes keratitis, a prevalent cause of infectious blindness. The hallmark of HSV is lifelong latent infections and viral reactivations, leading to recurrent lesions or asymptomatic shedding. HSV‐1 and HSV‐2 can cause recurrent, painful, and socially limiting genital lesions, which predispose to human immunodeficiency virus infections, and can lead to neonatal herpes infections, a life‐threatening condition for the newborn. Despite massive efforts, there is no vaccine against HSV, as both viruses share the capability to evade the antiviral defenses of human and to establish lifelong latency. Recurrent and primary HSV infections are treated with nucleoside analogs, but the treatments do not completely eliminate viral shedding and transmission. Drug‐resistant HSV strains can emerge in relation to long‐term prophylactic treatment. Such strains are likely to be resistant to other chemotherapies, justifying the development of novel antiviral treatments. The importance of developing new therapies against HSV has been recognized by the World Health Organization. In this review, we discuss the current approaches for developing novel antiviral therapies against HSV, such as small molecule inhibitors, biopharmaceuticals, natural products, gene editing, and oligonucleotide‐based therapies. These approaches may have potential in the future to answer the unmet medical need. Furthermore, novel approaches are presented for potential eradication of latent HSV.

show abstract

Trapa natans

Lim¹

2012

Edible Medicinal and Non-Medicinal Plants

View full text Add to dashboard Cite

Herbal Mixtures Containing the Mushroom Ganoderma lucidum Improve Recovery Time in Patients with Herpes Genitalis and Labialis

Abstract: Administration of WTTCGE to patients suffering from herpes genitalis and labialis appears to shorten the time required to obtain symptom relief as has been shown in a previous report.

Cited by 21 publications

References 4 publications

A review of the Experimental Approaches Used in Clinical Studies to Evaluate the Health Benefits of Plant Food Supplements Associated With Infectious Diseases

A review of the Experimental Approaches Used in Clinical Studies to Evaluate the Health Benefits of Plant Food Supplements Associated With Infectious Diseases

Current landscape in antiviral drug development against herpes simplex virus infections

Trapa natans

Contact Info

Product

Resources

About